Anders Jack sold $425K of RVMD
Anders Jack (Chief Financial Officer) sold 2,722 shares of Revolution Medicines, Inc. (RVMD) at $156.12 ($0.42M total) on 2026-06-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific insider sale size, price, and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment, but there is no new operational or financial information to drive a durable repricing.
What to watch
The article provides no follow-on context (e.g., other insider buys/sells, lockups, or changes in guidance), so the trading signal is likely weak.
Background
The article is an SEC Form 4 insider transaction disclosure for Revolution Medicines, Inc.
Ticker impact
Revolution Medicines CFO Anders Jack sold 2,722 shares for about $424,956 under a pre-arranged 10b5-1 plan, per Form 4 filed June 18.
Likely limited, with any impact confined to short-term sentiment around the filing date.
The filing is a Form 4 insider transaction with a stated 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.
Market effects
Minimal; insider sale in a single biotech does not reset sector fundamentals.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than negative expectations.
Key entities
- issuerRevolution Medicines, Inc.
Company whose CFO insider sale is disclosed on Form 4.
- insiderAnders Jack
Chief Financial Officer who sold shares.
- trading mechanism10b5-1 plan
Pre-arranged plan that typically reduces interpretive weight of insider selling.
